ArriVent collapses on disappointing lung cancer data

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 06 Oct, 16:12 UTC

More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.

science

Sources

• T2ArriVent collapses on disappointing lung cancer dataBioPharma Dive / Healthcare Dive / MedTech Dive06 Oct, 16:12